Skip to main content
OpenTrials
Completed

NCT Number: NCT02989064

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Following the dose escalation phase, additional subjects will be enrolled at the target cell dose range to further characterize safety and the effects at this cell dose.

The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells. When the MAGE-A10ᶜ⁷⁹⁶T cells are available, subjects will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by T cell infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with urothelial, melanoma or head and neck cancer.

Subjects will be seen frequently by the Study Physician after receiving their T cells for the next 6 months. After that, subjects will be seen every 3, 6, or 12 months according to the Schedule of Procedures. All subjects completing or withdrawing from the interventional portion of the study will enter a long term follow-up phase for observation of delayed adverse events and overall survival for 15 years post-infusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Urothelial Carcinoma Bladder Urothelial Carcinoma Carcinoma Carcinoma, Transitional Cell Head and Neck Cancer Head and Neck Neoplasms Melanoma Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplastic Processes Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent.
  • Subject has histologically confirmed diagnosis of any one of the following cancers: (A) urothelial cancer (transitional cell cancer of the bladder, ureter or renal pelvis), (B) melanoma, or (C) squamous cell carcinoma of the head and neck.
  • Subject is HLA-A*02:01 and/or HLA-A*02:06 positive.
  • Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
  • Subject meets disease-specific requirements per protocol
  • Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.
  • Subject's tumor shows positive MAGE-A10 expression
  • Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  • Subject has a left ventricular ejection fraction ≥50%.
  • Subject is fit for leukapheresis and has adequate venous access for the cell collection.
  • Female subject of childbearing potential (FCBP) must have a negative urine or serum pregnancy test or male subject must be surgically sterile or agree to use a double barrier contraception method or abstain from heterosexual activity with a female of childbearing potential starting at the first dose of chemotherapy and for 4 months thereafter.
  • Subject must have adequate organ function per protocol

Exclusion criteria

  • Subject is HLA-A*02:05 in either allele, HLA-B*15:01 and/or HLA-B*46:01 positive. Subject has any A*02 null allele (designated with an "N", e.g. A*02:32N) as the sole HLA-A*02 allele.
  • Subject has received or plans to receive excluded therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy per protocol
  • Subject that has toxicity from previous anti-cancer therapy must have recovered to ≤ Grade 1 prior to enrollment
  • Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
  • Subject had major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovered from any surgical related toxicities.
  • Subject has an electrocardiogram (ECG) showing clinically significant abnormality at Screening or showing an average QTc interval ≥450 msec in males and ≥470 msec in females (≥480 msec for subjects with bundle branch block [BBB]) over 3 consecutive ECGs. Either Fridericia's or Bazett's formula may be used to correct the QT interval.
  • Subject has symptomatic CNS metastases.
  • Subject has a history of chronic or recurrent severe autoimmune or immune mediated disease
  • Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening.
  • Subject has uncontrolled intercurrent illness
  • Subject has active infection with HIV, HBV, HCV or HTLV
  • Subject is pregnant or breastfeeding.

Treatment and study plan

Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

Genetic

Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1

Primary outcomes

  1. Number of subjects with adverse events (AE), including serious adverse events (SAE).

    Time frame: 3 years

    Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation; and cardiac assessments, including ECG/troponin.

  2. Evaluation of the persistence of genetically modified T cells

    Time frame: 3 years

    Evaluation of the persistence of the infused T cells in the periphery.

  3. Measurement of RCL in genetically modified T cells.

    Time frame: 3 years

    Evaluation of RCL in Subject PBMCs using PCR-based assay.

  4. Assessment of dose limiting toxicities to determine optimally tolerated dose range

    Time frame: 3 years

    Evaluation of dose limiting toxicities will be performed using the CTCAE Version 4.0

  5. Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).

    Time frame: 3 years

    Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1

  6. Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.

    Time frame: 3 years

    Evaluation of the efficacy of the treatment by assessment of time to first response.

  7. Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.

    Time frame: 3 years

    Evaluation of the efficacy of the treatment by assessment of duration of response.

  8. Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause.

    Time frame: 3 years

    Evaluation of the efficacy of the treatment by assessment of duration of stable disease.

  9. Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause

    Time frame: 3 years

    Evaluation of the efficacy of the treatment by assessment of progression-free survival.

  10. Interval between the date of first T cell infusion and date of death due to any cause.

    Time frame: 3 years

    Evaluation of the efficacy of the treatment by assessment of overall survival.

  11. Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)

    Time frame: 15 years post last treatment (infusion)

    • New occurrence of any malignancy
    • New occurrence or exacerbation of a pre-existing neurologic disorder
    • New occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder
    • New occurrence of a hematologic disorder
    • New occurrence of any opportunistic and/or serious infections
    • New occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy

Sponsors and collaborators

Lead sponsor

Adaptimmune

Industry

Registry information

Official study title

Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Dec 12, 2016
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.